Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications.

@article{Vermorken1982PharmacokineticsOF,
  title={Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications.},
  author={Jan Baptist Vermorken and Wim J.F. van der Vijgh and Ina Klein and Helen E. Gall and Herbert Michael Pinedo},
  journal={European journal of cancer \& clinical oncology},
  year={1982},
  volume={18 11},
  pages={
          1069-74
        }
}
Pharmacokinetics of c / s-Diammine-1 , 1-cyclobutane Dicarboxylate Platinum ( ll ) in Patients with Normal and Impaired Renal Function 1
TLDR
In vitro studies with plasma and urine demonstrated that, in contrast to cisplatin, CBDCA is a stable complex, and these differences in the pharmacokinetics may explain why the latter complex is not nephrotoxic.
Long-term pharmacokinetic behavior of platinum after cisplatin administration
TLDR
A close equilibrium between ultrafiltrable and total platinum (ratio, 6%) persisted for as long as 3 weeks after cisplatin administration, underline the importance of individual differences in platinum metabolism.
Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin
TLDR
In patients with normal renal and hepatic function, the free platinum AUC was identical for cisplatin infusions of different duration when equal doses were given, and the uptake of platinum in red blood cells was rapid, and peak concentrations correlated with the free Platinum AUC independent of the infusion schedule.
Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis - malonato[(4R, 5R )-4,5-bis(aminomethyl)- 2-isopropyl-1,3-dioxolane]platinum(II)
TLDR
It is strongly suggested that the therapeutic efficacy of SKI 2053R given by continuous long-term infusion should be investigated in future clinical studies.
Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin.
TLDR
The results suggest that increased antitumor effect and toxicity could occur in patients receiving sequential courses of cisplatin.
Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans
TLDR
It is suggested that a single measurement of plasma platinum concentration 24 h after i.v. infusion of cisplatin could be a simple method either of detecting patients with extreme values of AUC and Cp0 or of studying the evolution of these parameters during multiple courses of treatment, although it cannot be used to give precise values for A UC andCp0.
Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck.
TLDR
The concentration of platinum in the tumour did not correlate with the survival time of the patient, but was found to be correlated with the volume of distribution in the post-distributive phase.
...
...

References

SHOWING 1-10 OF 16 REFERENCES
Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II).
TLDR
Renal impairment was associated with extremely high plasma levels of filterable platinum but did not affect other pharmacokinetic parameters, and preliminary data on the distribution of cis-platinum to ascitic fluid are presented.
Clinical kinetics of intact cisplatin and some related species
TLDR
Larger doses of cisplatin resulted in higher plasma levels of all three species monitored, and although the increases appeared somewhat less than proportional to dose, terminal plasma slopes were not dose dependent.
Phase I study of cis-diamminedichloroplatinum(II) administered as a constant 5-day infusion.
TLDR
Dose-limiting toxicity was observed, manifested as marrow suppression and particularly thrombocytopenia in 13 of 14 patients evaluated at doses greater than or equal to 30 mg/m2/day, and gastrointestinal toxicity characteristic of bolus treatment schedules was less intense but was cumulative and dose-related.
Kinetics of cis‐dichlorodiammineplatinum
TLDR
The cancer chemotherapeutic cis‐dichlorodiammineplatinum (cis‐DDP) was administered to 8 patients and the non‐protein‐bound platinum was found to be rapidly and biphasically cleared from the plasma with half‐life values of 8 to 10 min and 40 to 45 min.
Clinical and pharmacological studies with cis-diamminedichloroplatinum (II).
TLDR
Renal impairment was the dose-limiting toxicity in the single-dose escalation scheme used, and progressive renal failure contributed to the death of one patient, this Phase I investigation characterizes the toxicity and pharmacological disposition of the drug in 10 patients.
Renal toxicity studies of protein-bound platinum(cis).
The effect of cis-diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications.
TLDR
Asynchronous human lymphoma cells treated for 1 hr with increasing concentrations of cis -diamminedichloroplatinum(II) (DDP) revealed a marked decrease in survival, which suggests that better antitumor results with less toxic effects may be obtained clinically by prolonged infusion of low doses of DDP.
Parmacokinetic evidence for an enterohepatic circulation in a patient treated with cis dichloro diammine platinum II)
TLDR
Platinum concentrations in plasma were measured during and after a 15 min intravenous infusion of cis-dichlorodiamineplatium (II) (cis-platinum) at a dose of 100 mg/m2 to indicate the presence of an enterohepatic circulation.
24‐Hour infusion of cis‐platinum in head and neck cancers
TLDR
The dosage of 80 mg/m2 administered over 24 hours gives a response rate in head and neck cancers equivalent to that reported with higher doses given by rapid infusion, and toxicity is minimal.
...
...